B cell

Autoimmunity Assays

  • Antibody production (Total IgG)
  • Memory B cell Antibody Isotypes
  • Naïve B cells Isotype switching
  • B cell proliferation/activation/cytokine secretion
  • Antigen presentation

Tonsillar re-aggregate model

Tonsils are a secondary lymphoid tissue rich in B cell subsets and the specialized, anatomically restricted T follicular helper (Tfh) subset of CD4 T cells. Tonsils provide an accessible source of cells for those interested in B cell immunology, Tfh biology and vaccine development. The tonsillar cell re-aggregate model provides functional insight into human germinal center biology, allowing measurement of key features including naive B cell differentiation, plasma cell/plasmablast differentiation, and antibody production.

Figure A. Schematic representation of tonsil re-aggregate model. Cells are seeded at high density in 96 well plates; unstimulated (US) or stimulated with quadrivalent inactivated influenza vaccine (IIV) in the presence of vehicle or reference inhibitors such as Rapamycin. B cell readouts include B cell phenotyping, B cell proliferation and hemagglutinin (HA)-specific IgG by ELISPOT or ELISA.
Figure B. Flow plots representing B cell subpopulations. C. Bar graphs showing frequencies of each B cell subpopulation.
Figure D. Flow plots representing total B cell proliferation. E. Bar graphs showing frequencies of divided B cells. Gating strategy: CD45+ > Viable > FSC vs SSC > Singlets > CD4-CD8- > CD19hi/lo
Figure F. HA-specific IgG production on day 7 measured by ELISpot. Representative images from one donor (left) and bar graph showing spot forming units (SFU) per 200,000 cells from 3 pre-selected IIV responsive donors run in duplicate wells (right). G. HA-specific IgG secretion on day 12 by ELISA. Representative dilution curves from one donor

Drug Discovery Tool

Find the right immune assay for your therapeutic area, modality and target using this interactive Drug Discovery Tool.

Explore now
Speak to a Scientist

Learn how the Nexus BioQuest team can help with your pre-clinical drug discovery programs.

Schedule a call